michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Josh.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thanks for taking my quick [Phonetic] questions and welcome Ken as well. Maybe start off with the Cree business. I'm not trying to steal any thunder from your Analyst Day. But, Mark, can you talk about your general philosophy related to that business? What are your priorities there? Is that mostly the two technology transitions that you talked about in your prepared remarks? And, Ken, related to that, you talk about the gross margin goal in the near term, maybe a little longer term, but at the operating margin level, that line, the fiscal Q3 will be more like mid-single digit range, just based on numbers you gave. How are you thinking about that operating margin line over time?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey Michael.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. It was predominantly Aerospace, but we did see shortages in the disruptions on both sides. We've all read about the electronics, and that's probably the predominant area that we're seeing shortages come from. But there is a variety of things. We've got plant shutdowns or at least slowdowns related to COVID and related to other issues. So there've just been a variety of things that I think with respect to getting things back up and running and with respect to the announced shortages that we're seeing impact us going forward. We do believe our supply chain, we stay very close to them. They have plans to alleviate the issues, but it's going to continue for a while here.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure, so temanogrel both have Fast Track designation, and we're moving both into Phase 2. Just to recap, temanogrel, we're taking the microvascular obstruction, we'll be looking at a subset of patients, we'll be looking at patients, and we'll be looking at actual resistances as measured quantitatively, distal to the site of the occlusion and in those patients. And so, that's really design of the study. It will be an international cath lab. And then similarly, in the APD418 space, those will also be in an international cath lab, with this quantitative set of metrics as we can possibly develop in that setting.
Again, we're trying to look for real clear measures there of cardiac output and ejection fraction, and no change in hemodynamics. So we'll be able to do that again in a controlled setting. So both those studies are really designed as very important proof of concept studies, to begin to inform, and work with the agency on where to go next in terms of a registrational program. And both of those data readouts are in the '22 timeframe?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I guess, going after it is where it starts. So we see how we go.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, so we believe that we have a pretty attractive platform right now. We continue to see opportunities to hire great talent. And we now continue to sort of evaluate that. And so finding those great people who have experience in SBA primarily, we continue to think we've got great opportunity. In terms of new verticals, we continue to look at a few here and there, they'll be kind of tuck-in ones if from that perspective, no real major splash in the infrastructure space, in renewables, we still see adjacencies there. And then in the sponsor lending that we're doing, we're broadening that just like the generalist and SBA broaden that aperture of the industry who look at, so do the sponsor lending group as well. So we broaden out of the specific industries a bit as we go into some of those more horizontal businesses that we're into.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Sean.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, I mean, for so all of the patients will likely be included for safety. Of course, I think your question is really at efficacy. And sort of two important points, I mean, that the thought would be that, the patients after going at the RP2D would be the ones that would be included. But of course, the FDA is going to look at every patient, and you're going to include every patient in an eventual filing.
The other thing, of course is, this will ultimately be a review issue, as it always is for FDA. So FDA is guiding us to ensure that those patients have the potential of being counted, or being, being included in the ultimate registrational cohort. But that's that, I don't want to misrepresent, that's ultimately going to be an FDA review issue. But it allows us, as we started rolling these Phase 1 expansion cohorts to move more quickly, more aggressively against that ultimate endpoint, which we're very focused on.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, sure. I think it's fair to say and we commented on it that the retention is at an all-time record for a Q1. So that's fantastic and better than we had expected. The expectation as we went into the year was to see, particularly in the smaller business segment, to see that slip back a little and indeed it has, but it hasn't slipped back nearly to the extent that we had anticipated. So we're even better there against what we had previously thought. Of course, then that means that we did have and continue to have good retention levels in the midmarket and the upmarket. So we expect that to continue.
However, as you know the cyclicality of our business and the seasonality of our business, we will need to get through the calendar year end, which is when we see most of the switching activity because of the drivers in the new starts to the year, etc. So we are positive and we did take our retention estimate up for the year and we'll see if it holds and perhaps is better than we expected.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Bob's not a creative guy, so I can't do anything creative because he won't respond to it, Joel. He's just being a potato. So I -- we just have to make sure we're finding assets that have great synergies and good strong organic growth programs embedded in their businesses. And I think when you look at where we are in the construction products or in CFT or even in CIT and medical, there are businesses that have great products, that have good runways with strong organic growth and luckily in those markets we now -- even in medical, we've got basis that are big enough that we can make acquisitions and get synergies out of it. And so I think that's the only way we can make the model work is, we have to have good strong organic growth and leverage with those synergies.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, thank you. Good morning, everyone. First one for Craig. Trying to reconcile your fiscal Q1 net admin fees revenue of around $150 million and the guidance is $570 to $590 million for the full year.
Based on historical trends, fiscal Q1 is generally the seasonally weakest quarter for you guys from net admin fees point of view. So guidance seems to imply some moderation here. Can you help us reconcile that, that why the guidance is unchanged with that Q1 number?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Let me try and break it down for you this way, Brian, and see if it helps. But as we compare to 2020 revenues at BTD to our current view, we're seeing about a $96 million increase in revenues. So that's 47%. But of that, $56 million is material pricing between our 2020 results in revenues and what we are forecasting this year. So then there's $40 million of, if you will, growth as it relates to the value-add that we're doing to our customers.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. This is Clarke Jeffries on for Brent. First question is, looking at some of the new and expansion customers highlighted over the past few quarters, I think we continue to stand out is the traction verticals outside of software and business services. The first part of the question is, how would you characterize the contribution from those customers in driving the acceleration in $100,000 deals? And then second part, is there a potential narrative here that some of the traditional industries maybe have overinvested in systems that improve the B2B process, whether that was workflow automation invoicing, but there maybe wasn't an awareness in sales intelligence and where there could be an opportunity to lift the total overall funnel of opportunities.
And what we're seeing today is really that market awareness being unlocked.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I mean I'll let Todd embellish as needed. But there is a significant factor associated with optimization and in particular feedstock costs.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So Paul, you're right. Q4 was better than we anticipated in PCR. So for the full-year, as Jason just mentioned, it was down about $300 million. We had signaled that it could be about $350 million, so a slight improvement. We do think it will continue to improve in 2021. And in fact, at this point, overall, I think our expectation is that it can grow. Now, it will be incrementally as these number of different key verticals like transportation, airline, hospitality, oil and gas as they improve, but 2020 was pretty draconian. I look at it as more or less a floor, and our expectation is for PCR to return to growth in 2021. Now having said that, we still have to operate and execute on that against the supply constraints and limitations that are in front of us, but as we've started out the year in 2021, it's a good start.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I thought that would be the easiest answer, Brent. I mean...

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Look, we're thrilled with -- I thought it was just a brilliant move on Wyndham Destinations, apart from a rebranding standpoint, it is a great brand. Our Blue Thread sales, if you were following, yesterday, essentially, when you look at sales, doubled year-on-year from 7% to 14%, we're incentivized on that -- on those new owner sales. And we're doing everything we possibly can to -- and there are so many new initiatives our two teams are working on to continue to drive new owner sales for travel and leisure. We think there's a lot more we could do together on the call center marketing front, on the CMP lobby marketing.
There's a lot of our franchisees that would love the opportunity to have T&L take over their front desk from a concierge standpoint and provide their guests with services. And the Blue Thread transactions increased. As Mike Braun said yesterday in his call, 200 basis points to 9% of their transactions. There's really no change to the timeshare sales strategy or the timeshare Wyndham branding that we use from a redemption standpoint, it offers us. Our Wyndham Rewards program just continues to strengthen with all of the great additions that come into the travel and leisure world. And so, we're very optimistic about the future, and our teams are working really well together. Michele, did you want to add anything to that?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, four states have eliminated them. Many of the states that are on January one rating cycles have not yet declared whether they will continue them or not. The only one that actually is formally continued into next year is in Mississippi. So it's hard to say. As they're announced either to be eliminated or to persist and whether they persist for a full year or half year is just largely unknown at this time. So I think your point is a correct one. It -- whatever happens, we'll likely expect our quarter-to-quarter results next year. Whether it's back-ended or front-end loaded, I don't know yet, but the only corridor that actually has been announced that persists into 2022 because their state fiscal year straddles the calendar year is Mississippi.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Thanks, Matt. This is Tim. We are still seeing increased demand for capacity in this space as we continue to on-board new customers. Of the two new customers we did on-board last quarter, we publicly announced that one of those customer, Humanigen [Phonetic], which is obviously COVID-related and -- but also has some non-COVID-related indications for the program that we're working on there as well. But we will continue to work to on-board new customers quarter-over-quarter and year-over-year.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I just had a simple question on Slide 6. The disparity in organic growth between the U.S. and rest of the world, is the right way to interpret that, that the ICON disposition is underpinned in the U.S.? Or is there other [Indecipherable] approaching organic growth rate? Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, John.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Ronny.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I mean, if you go back, I mean, the analogy is, if you look at the 819 protocols that we have, where the 819 protocol has single dose and multi dosing, as well as the 576 protocol that has single dose and multi dosing, you essentially clear a single dose level of say, pick it 100 million cells. Once you clear that single dose level of 100 million cells, you can begin multi dosing with that cleared dose level. So you could do 2 100 million cell doses.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, everyone, for taking the time and for your attention. Really appreciate the questions. Have a great one.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, and congratulations on the quarter. Quite remarkable. Greg, you made a comment about the higher proportion of distress business in the market, and I just want to make sure I was interpreting the comment correctly. Are you talking about essentially more of the business going into excess and surplus lines or are you speaking more along the lines of just the businesses themselves are struggling with the economy?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks for taking my questions. I have two for Philipp. The first one, and I appreciate all the color on retail and commerce, the merchant community growing so strong the last year. I'd be curious to hear about your discussions now with merchants and sort of what the largest friction points that they are looking for you to solve and sort of continue to help them as the world reopens, the kind of the merchant discussions. And then secondly, a question on one of the earlier products on Discover Feed. Would love to hear about sort of early learnings on Discover Feed and how you think about hurdles you need to overcome to monetize that.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, it's again -- I mean I think what we have found, and we have found this again throughout the entire pandemic period, is that as COVID volumes rise and they peak that our volumes of elective and scheduled procedures and non-COVID business tends to decline and I think we certainly experience that in Q1. So in the January timeframe when COVID volumes were peaking, I would say that surgical and elective procedures were probably at 75% or 80% of pre-pandemic levels. I think by the end of the quarter as COVID volumes had declined pretty measurably, we were at 95%-plus of pre-pandemic elective and surgical volumes. And I think those trends have continued into April as well.

    Prediction (one of UP, DOWN, SAME): SAME